Table S1: Mouse AKR Vs DBA Tumor Gene List Probe Set GB Acc Symbol

Total Page:16

File Type:pdf, Size:1020Kb

Table S1: Mouse AKR Vs DBA Tumor Gene List Probe Set GB Acc Symbol Table S1: Mouse AKR vs DBA tumor gene list Probe set GB acc Symbol UGCluster 1425583_at BC010605 1425614_x_at M83244 H2-D1 Mm.33263 1427651_x_at X00246 H2-L /// H2-D1 Mm.33263 1419157_at AI428101 Sox4 Mm.240627 1422565_s_at NM_008688 1452544_x_at J00406 H2-D1 Mm.33263 AFFX-BioB-M_at 1425584_x_at BC010605 AFFX-r2-Ec-bioB-M_at 1426278_at AY090098 2310061N23Rik Mm.271275 1423411_at BI099836 BC013481 Mm.332406 1459725_s_at C86550 Dcpp Mm.287985 1419327_at NM_053181 AA415817 Mm.171484 AFFX-r2-Ec-bioB-3_at 1455869_at BG862223 1416770_at NM_021537 Stk25 Mm.28761 AFFX-r2-Ec-bioB-5_at 1418283_at NM_009903 Cldn4 Mm.7339 1424775_at BC018470 Oas1g Mm.14301 1428850_x_at AK004342 2410026K10Rik Mm.260878 1426633_s_at AW553424 D7Ertd760e 1427932_s_at BI076834 1200003I10Rik /// 1200015M12RikMm.332931 /// 1200016E24Rik 1449289_a_at BF715219 B2m Mm.163 AFFX-r2-Ec-bioC-3_at 1426632_at AW553424 D7Ertd760e 1448207_at BC010840 Lasp1 Mm.271967 1450017_at BG065754 Ccng1 Mm.2103 1451777_at BC013672 BC013672 Mm.33332 1420352_at NM_133731 Prss22 Mm.157351 1423747_a_at BC027196 Pdk1 Mm.34411 1454169_a_at AK017174 Epsti1 Mm.68134 1448793_a_at BC005679 Sdc4 Mm.3815 AFFX-r2-Ec-bioC-5_at 1425161_a_at BC005574 5730502D15Rik 1423158_at AK008566 Gnpnat1 Mm.233534 1453196_a_at BQ033138 Oasl2 Mm.228363 1449250_at NM_033573 Prcc Mm.35089 1452428_a_at AI099111 B2m Mm.163 1421024_at BB524140 Agpat1 Mm.8684 1450016_at BG065754 Ccng1 Mm.2103 1419043_a_at BM239828 AW111922 Mm.326506 1449262_s_at BB704337 Lin7c Mm.235300 1426975_at BG067859 4632413K17Rik Mm.295246 1426164_a_at AF479773 Usf1 Mm.8 1417461_at NM_007598 Cap1 Mm.8687 1424101_at BC027206 Hnrpl Mm.331189 1438758_at AU046270 1430575_a_at BB484264 Tpp2 Mm.234139 1459909_at BI249259 1451593_at BC018402 H2-Q1 Mm.214762 1422772_at NM_052993 C1galt1 Mm.102752 1450396_at NM_021465 Stag2 Mm.290422 1416986_a_at AB018194 Ptpns1 Mm.1682 1425521_at BC019726 Paip1 Mm.132584 1421014_a_at BC023398 Clybl Mm.34608 1456262_at BE446879 Rbm5 Mm.259197 1422179_at NM_008127 Gjb4 Mm.56906 1450576_a_at NM_013651 Sf3a2 Mm.262677 1418003_at NM_025427 1190002H23Rik Mm.29811 1427037_at BF227830 Eif4g1 Mm.260256 1452540_a_at M25487 Hist1h2bc /// Hist1h2beMm.314098 /// Hist1h2bp 1451683_x_at M34962 H2-L /// H2-D1 Mm.33263 1419042_at BM239828 AW111922 Mm.261140 1426713_s_at BM238943 Eprs Mm.154511 1416374_at AF242857 Ap3m1 Mm.300064 1436737_a_at BB737680 Sorbs1 Mm.210815 1451640_a_at BC008229 1500011J06Rik Mm.276341 1449145_a_at AB029929 Cav1 Mm.28278 1422102_a_at BC024319 Stat5b Mm.34064 1418280_at NM_011803 Copeb Mm.275036 1418191_at NM_011909 Usp18 Mm.326911 1434676_at BM118290 1419066_at NM_030244 Ier5l Mm.295464 1427471_at BF782863 Fbxl3a Mm.214746 1418527_a_at NM_010178 Fusip1 Mm.10229 1452294_at AK008111 2010005A06Rik Mm.36560 1448997_at AB013464 Pscd1 Mm.86413 1416101_a_at NM_015786 Hist1h1c Mm.193539 1419416_a_at NM_011244 Rarg Mm.1273 1419032_at AW556821 2610018G03Rik Mm.46254 1430514_a_at AK002762 2410026K10Rik Mm.260878 1417065_at NM_007913 1431213_a_at BG297038 1450006_at NM_019744 Ncoa4 Mm.275762 1422736_at NM_019930 Ranbp9 Mm.148781 1451931_x_at M69068 H2-L /// H2-D1 Mm.33263 1450170_x_at NM_010380 H2-L /// H2-D1 Mm.33263 1453556_x_at AK002762 2410026K10Rik Mm.260878 1451860_a_at AF220015 Trim30 Mm.295578 1436898_at BI738328 Sfpq Mm.257276 1449875_s_at NM_010395 H2-T10 Mm.87776 1425281_a_at AF201289 Dsip1 Mm.22216 1436320_at W45978 Mm.178550 1448309_at AF242857 Ap3m1 Mm.300064 1417229_at AF084459 Capn1 Mm.6221 1421491_a_at NM_029478 4930579A11Rik Mm.243797 1451564_at BC021340 1600029O10Rik Mm.244406 1426787_at AW744519 2310047I15Rik Mm.236878 1433674_a_at BQ177137 Rnu22 1427175_at BC004761 AI428936 Mm.227325 1418580_at BC024872 5830458K16Rik Mm.180157 1419816_s_at AI788755 1300002F13Rik Mm.249333 1418019_at NM_007754 Cpd Mm.276736 1451034_at BG094962 Zfp36l2 Mm.347400 1450033_a_at AW214029 Stat1 Mm.277406 1421025_at BB524140 Agpat1 Mm.8684 1422044_at AF074926 Ndst1 Mm.181862 1423748_at BC027196 Pdk1 Mm.34411 1452519_a_at X14678 AFFX-BioB-5_at 1420170_at C80049 Myh9 Mm.29677 1417133_at NM_008885 Pmp22 Mm.1237 1454106_a_at AK017941 Cxxc1 Mm.17537 1425028_a_at BC024358 Tpm2 Mm.646 1451908_a_at BC005766 Sec14l1 Mm.272312 1427276_at BI665568 Smc4l1 Mm.206841 1434380_at BM241271 Mm.254851 1448805_at NM_009480 Usf1 Mm.8 1438390_s_at AV105428 Pttg1 Mm.6856 1424518_at BC020489 1435137_s_at BB119177 1200015M12Rik 1418536_at M29881 H2-Q7 Mm.34421 1425336_x_at BC011306 H2-K1 Mm.196032 1425502_x_at BC003207 1452364_at BG066534 D11Ertd530e Mm.283410 1454699_at BG076140 Sesn1 Mm.276226 1417459_at NM_019910 Dcpp Mm.287985 1456398_at BB648848 1417613_at BF147705 Ier5 Mm.12246 1417084_at NM_010124 Eif4ebp2 Mm.259516 1417793_at NM_019440 AI481100 Mm.301384 1449199_at NM_013605 Muc1 Mm.16193 1427262_at L04961 Xist 1427746_x_at S70184 H2-K1 Mm.16771 1421322_a_at NM_008394 Isgf3g Mm.2032 1451501_a_at BC024375 Ghr Mm.3986 1416204_at BC019391 Gpd1 Mm.252391 1429040_at BE692399 2610005L07Rik Mm.157360 1425545_x_at M86502 H2-L 1420899_at AW542340 Rab18 Mm.132802 1460194_at NM_010726 Phyh Mm.27066 1455930_at BI651113 1426478_at AA124924 Rasa1 Mm.259653 1449740_s_at C79957 Dsg2 Mm.345891 1426051_a_at BC006628 Cenpb 1431008_at BG916808 0610037M15Rik Mm.221293 1431686_a_at AK013970 Gmfb Mm.87312 1420948_s_at BB825830 4833408C14Rik 1421789_s_at NM_007478 Arf3 Mm.221298 1450846_at AV144956 Bzw1 Mm.261831 1427387_a_at L04678 Itgb4 Mm.213873 1421009_at BB741897 2510004L01Rik Mm.24045 1418072_at NM_023422 1421754_at NM_133243 AY036118 1417141_at NM_018738 Igtp Mm.33902 1450034_at AW214029 Stat1 Mm.277406 1423754_at BC010291 Ifitm3 Mm.141021 1449025_at NM_010501 Mm.353948 1451018_at BF658789 Leprotl1 Mm.34212 1426324_at M33151 H2-L /// H2-D1 /// H2-K1Mm.196032 /// H2-Q2 /// H2-Bl 1451426_at AF316999 D11Lgp2e Mm.271830 1419927_s_at AW549708 Rabif Mm.198119 1452747_at BM944122 1110012E06Rik Mm.205625 1452254_at BB292990 Mtmr9 Mm.259107 1422141_s_at NM_033616 Csprs Mm.248553 1428106_at AK004841 1300001I01Rik Mm.214574 1449009_at NM_011579 Tgtp Mm.338891 1427319_at AI607603 A230046K03Rik Mm.278577 1424617_at BC008158 Ifi35 Mm.45558 1430999_a_at BM932452 Scoc Mm.219245 1423711_at BC018422 Ndufaf1 Mm.5390 1427882_at AK016368 4930588M11Rik Mm.278808 1417601_at NM_015811 Rgs1 Mm.103701 1431645_a_at AK013104 Gdi3 Mm.153226 1422962_a_at NM_010724 Psmb8 Mm.180191 1416732_at BB166592 Top2b Mm.130362 1421060_at AF312858 Mllt1 Mm.148748 1449029_at NM_021462 Mknk2 Mm.42126 1432004_a_at AK015410 Dnm2 Mm.39292 1416421_a_at BG796845 Ssb Mm.10508 1426888_at BI412952 Bat8 Mm.35345 1448117_at BB815530 Kitl Mm.45124 1416016_at AW048052 Tap1 Mm.207996 1436343_at BM502696 Chd4 Mm.333388 1450392_at BB144704 Abca1 Mm.277376 1417889_at NM_009694 Apobec2 Mm.281793 1422140_at NM_033616 1423555_a_at BB329808 Ifi44 Mm.30756 1450240_a_at NM_031393 Sytl1 Mm.25660 1425716_s_at AF402617 Bak1 Mm.2443 1418020_s_at NM_007754 Cpd Mm.276736 1452439_s_at AF250135 Sfrs2 Mm.21841 1430053_a_at AK019142 2810409H07Rik Mm.22661 1419024_at BC003761 Ptp4a1 Mm.262000 1423072_at AW549928 6720475J19Rik Mm.275739 1450783_at NM_008331 Ifit1 Mm.6718 1438676_at BM241485 AI595338 Mm.354723 1422892_s_at U13648 H2-Ea Mm.15680 Table S2:Probe sets with significant variation in human datasets from the Mouse AKR vs DBA tumor comparison Probe set GSE1456 GSE2034 GSE3494 GSE4922 Rosetta Gene Symbol Gene Title 200008_s_at 200008_s_at200008_s_at200008_s_at200008_s_at 0 GDI2 GDP dissociation inhibitor 2 200009_at 200009_at 0 200009_at 200009_at 0 GDI2 GDP dissociation inhibitor 2 200011_s_at 200011_s_at 0 200011_s_at200011_s_at 0 ARF3 ADP-ribosylation factor 3 200618_at 200618_at 0 200618_at 200618_at NM_006148 LASP1 LIM and SH3 protein 1 200625_s_at 200625_s_at 0 0 0 0 CAP1 CAP, adenylate cyclase-associated protein 1 (yeast) 200730_s_at 200730_s_at 0 200730_s_at200730_s_atNM_003463 PTP4A1 protein tyrosine phosphatase type IVA, member 1 200731_s_at 200731_s_at 0 200731_s_at200731_s_atNM_003463 PTP4A1 protein tyrosine phosphatase type IVA, member 1 200732_s_at 200732_s_at 0 200732_s_at200732_s_atNM_003463 PTP4A1 protein tyrosine phosphatase type IVA, member 1 200733_s_at 200733_s_at 0 200733_s_at200733_s_atNM_003463 PTP4A1 protein tyrosine phosphatase type IVA, member 1 200734_s_at 200734_s_at 0 200734_s_at200734_s_at 0 ARF3 ADP-ribosylation factor 3 200752_s_at 200752_s_at 0 0 0 0 CAPN1 calpain 1, (mu/I) large subunit 200753_x_at 200753_x_at 0 200753_x_at200753_x_at 0 SFRS2 splicing factor, arginine/serine-rich 2 200841_s_at 200841_s_at200841_s_at200841_s_at200841_s_atNM_004446 EPRS glutamyl-prolyl-tRNA synthetase 200842_s_at 200842_s_at200842_s_at200842_s_at200842_s_atNM_004446 EPRS glutamyl-prolyl-tRNA synthetase 200843_s_at 200843_s_at 0 200843_s_at200843_s_atNM_004446 EPRS glutamyl-prolyl-tRNA synthetase 200887_s_at 200887_s_at 0 200887_s_at200887_s_atNM_007315 STAT1 signal transducer and activator of transcription 1, 91kDa 201138_s_at 201138_s_at 0 201138_s_at201138_s_atNM_003142 SSB Sjogren syndrome antigen B (autoantigen La) 201139_s_at 201139_s_at 0 0 0 NM_003142 SSB Sjogren syndrome antigen B (autoantigen La) 201183_s_at 201183_s_at 0 201183_s_at201183_s_at 0 CHD4 chromodomain helicase DNA binding protein 4 201367_s_at 201367_s_at201367_s_at201367_s_at201367_s_at 0 ZFP36L2 zinc finger protein 36, C3H type-like 2 201368_at 201368_at 0 201368_at 201368_at 0 ZFP36L2 zinc finger protein 36, C3H type-like 2 201369_s_at 201369_s_at201369_s_at201369_s_at201369_s_at 0 ZFP36L2 zinc finger protein 36, C3H type-like 2 201394_s_at 201394_s_at 0 201394_s_at201394_s_atNM_005778 RBM5 RNA binding motif protein 5 201416_at 201416_at
Recommended publications
  • Types of Acute Phase Reactants and Their Importance in Vaccination (Review)
    BIOMEDICAL REPORTS 12: 143-152, 2020 Types of acute phase reactants and their importance in vaccination (Review) RAFAAT H. KHALIL1 and NABIL AL-HUMADI2 1Department of Biology, College of Science and Technology, Florida Agricultural and Mechanical University, Tallahassee, FL 32307; 2Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA Received May 10, 2019; Accepted November 25, 2019 DOI: 10.3892/br.2020.1276 Abstract. Vaccines are considered to be one of the most human and veterinary medicine. Proteins which are expressed cost-effective life-saving interventions in human history. in the acute phase are potential biomarkers for the diagnosis The body's inflammatory response to vaccines has both of inflammatory disease, for example, acute phase proteins desired effects (immune response), undesired effects [(acute (APPs) are indicators of successful organ transplantation phase reactions (APRs)] and trade‑offs. Trade‑offs are and can be used to predict the ameliorative effect of cancer more potent immune responses which may be potentially therapy (1,2). APPs are primarily synthesized in hepatocytes. difficult to separate from potent acute phase reactions. The acute phase response is a spontaneous reaction triggered Thus, studying acute phase proteins (APPs) during vaccina- by disrupted homeostasis resulting from environmental distur- tion may aid our understanding of APRs and homeostatic bances (3). Acute phase reactions (APRs) usually stabilize changes which can result from inflammatory responses. quickly, after recovering from a disruption to homeostasis Depending on the severity of the response in humans, these within a few days to weeks; however, APPs expression levels reactions can be classified as major, moderate or minor.
    [Show full text]
  • Genome-Wide Analysis of 5-Hmc in the Peripheral Blood of Systemic Lupus Erythematosus Patients Using an Hmedip-Chip
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 35: 1467-1479, 2015 Genome-wide analysis of 5-hmC in the peripheral blood of systemic lupus erythematosus patients using an hMeDIP-chip WEIGUO SUI1*, QIUPEI TAN1*, MING YANG1, QIANG YAN1, HUA LIN1, MINGLIN OU1, WEN XUE1, JIEJING CHEN1, TONGXIANG ZOU1, HUANYUN JING1, LI GUO1, CUIHUI CAO1, YUFENG SUN1, ZHENZHEN CUI1 and YONG DAI2 1Guangxi Key Laboratory of Metabolic Diseases Research, Central Laboratory of Guilin 181st Hospital, Guilin, Guangxi 541002; 2Clinical Medical Research Center, the Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong 518020, P.R. China Received July 9, 2014; Accepted February 27, 2015 DOI: 10.3892/ijmm.2015.2149 Abstract. Systemic lupus erythematosus (SLE) is a chronic, Introduction potentially fatal systemic autoimmune disease characterized by the production of autoantibodies against a wide range Systemic lupus erythematosus (SLE) is a typical systemic auto- of self-antigens. To investigate the role of the 5-hmC DNA immune disease, involving diffuse connective tissues (1) and modification with regard to the onset of SLE, we compared is characterized by immune inflammation. SLE has a complex the levels 5-hmC between SLE patients and normal controls. pathogenesis (2), involving genetic, immunologic and envi- Whole blood was obtained from patients, and genomic DNA ronmental factors. Thus, it may result in damage to multiple was extracted. Using the hMeDIP-chip analysis and valida- tissues and organs, especially the kidneys (3). SLE arises from tion by quantitative RT-PCR (RT-qPCR), we identified the a combination of heritable and environmental influences. differentially hydroxymethylated regions that are associated Epigenetics, the study of changes in gene expression with SLE.
    [Show full text]
  • Influence of Infection and Inflammation on Biomarkers of Nutritional Status
    A2.4 INFLUENCE OF INFECTION AND INFLAMMATION ON BIOMARKERS OF NUTRITIONAL STATUS A2.4 Influence of infection and inflammation on biomarkers of nutritional status with an emphasis on vitamin A and iron David I. Thurnham1 and George P. McCabe2 1 Northern Ireland Centre for Food and Health, University of Ulster, Coleraine, United Kingdom of Great Britain and Northern Ireland 2 Statistics Department, Purdue University, West Lafayette, Indiana, United States of America Corresponding author: David I. Thurnham; [email protected] Suggested citation: Thurnham DI, McCabe GP. Influence of infection and inflammation on biomarkers of nutritional status with an emphasis on vitamin A and iron. In: World Health Organization. Report: Priorities in the assessment of vitamin A and iron status in populations, Panama City, Panama, 15–17 September 2010. Geneva, World Health Organization, 2012. Abstract n Many plasma nutrients are influenced by infection or tissue damage. These effects may be passive and the result of changes in blood volume and capillary permeability. They may also be the direct effect of metabolic alterations that depress or increase the concentration of a nutrient or metabolite in the plasma. Where the nutrient or metabolite is a nutritional biomarker as in the case of plasma retinol, a depression in retinol concentrations will result in an overestimate of vitamin A deficiency. In contrast, where the biomarker is increased due to infection as in the case of plasma ferritin concentrations, inflammation will result in an underestimate of iron deficiency. Infection and tissue damage can be recognized by their clinical effects on the body but, unfortunately, subclinical infection or inflammation can only be recognized by measur- ing inflammation biomarkers in the blood.
    [Show full text]
  • Role of Myeloid-Derived Suppressor Cells in Tumor-Associated Pregnancy
    MASTER THESIS IN MEDECINE No 747 Role of Myeloid-Derived Suppressor Cells in tumor-associated pregnancy Student Sabine Waeber Tutor Prof. Ivan Stamenkovic Institute of Pathology, CHUV Supervisor Marie-Aude Le Bitoux, Postdoctoral Fellow Expert Prof. Michel Aguet Institute of Pathology, EPFL-ISREC Lausanne, December 2012 1 ABSTRACT 3 INTRODUCTION 4 1. Tumor-host interactions ......................................................................................................................... 4 2. Metastasis during pregnancy .................................................................................................................. 4 3. Immunity & pregnancy ........................................................................................................................... 5 4. MDSC and their potential role in pregnancy .......................................................................................... 5 SPECIFIC AIMS OF THE STUDY 7 RESULTS & DISCUSSION 8 1. Gene expression profiles of MDSC extracted from pregnant mice display features that may augment permissiveness for tumor progression ............................................................................................................. 8 1.1. Results 8 1.1.1. Enrichment of MDSC 8 1.1.2. Hybridization on Affymetrix microarrays 9 1.1.3. Validation of microarray results by qReal-Time RT-PCR 11 1.1.4. Comparison of MDSC genes expressed in pregnant and tumor-bearing mice 12 1.2. Discussion 13 2. MDSC functions during human pregnancy .........................................................................................
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2
    Supplementary Table 3 Complete list of RNA-Sequencing analysis of gene expression changed by ≥ tenfold between xenograft and cells cultured in 10%O2 Expr Log2 Ratio Symbol Entrez Gene Name (culture/xenograft) -7.182 PGM5 phosphoglucomutase 5 -6.883 GPBAR1 G protein-coupled bile acid receptor 1 -6.683 CPVL carboxypeptidase, vitellogenic like -6.398 MTMR9LP myotubularin related protein 9-like, pseudogene -6.131 SCN7A sodium voltage-gated channel alpha subunit 7 -6.115 POPDC2 popeye domain containing 2 -6.014 LGI1 leucine rich glioma inactivated 1 -5.86 SCN1A sodium voltage-gated channel alpha subunit 1 -5.713 C6 complement C6 -5.365 ANGPTL1 angiopoietin like 1 -5.327 TNN tenascin N -5.228 DHRS2 dehydrogenase/reductase 2 leucine rich repeat and fibronectin type III domain -5.115 LRFN2 containing 2 -5.076 FOXO6 forkhead box O6 -5.035 ETNPPL ethanolamine-phosphate phospho-lyase -4.993 MYO15A myosin XVA -4.972 IGF1 insulin like growth factor 1 -4.956 DLG2 discs large MAGUK scaffold protein 2 -4.86 SCML4 sex comb on midleg like 4 (Drosophila) Src homology 2 domain containing transforming -4.816 SHD protein D -4.764 PLP1 proteolipid protein 1 -4.764 TSPAN32 tetraspanin 32 -4.713 N4BP3 NEDD4 binding protein 3 -4.705 MYOC myocilin -4.646 CLEC3B C-type lectin domain family 3 member B -4.646 C7 complement C7 -4.62 TGM2 transglutaminase 2 -4.562 COL9A1 collagen type IX alpha 1 chain -4.55 SOSTDC1 sclerostin domain containing 1 -4.55 OGN osteoglycin -4.505 DAPL1 death associated protein like 1 -4.491 C10orf105 chromosome 10 open reading frame 105 -4.491
    [Show full text]
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Chromosomal Rearrangements Are Commonly Post-Transcriptionally Attenuated in Cancer
    bioRxiv preprint doi: https://doi.org/10.1101/093369; this version posted February 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Chromosomal rearrangements are commonly post-transcriptionally attenuated in cancer 1 3 1 3, 4, 5 Emanuel Gonçalves ,​ Athanassios Fragoulis ,​ Luz Garcia-Alonso ,​ Thorsten Cramer ,​ ​ ​ ​ ​ 1,2# 1# Julio Saez-Rodriguez ,​ Pedro Beltrao ​ ​ 1 ​ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridge CB10 1SD, UK 2 ​ RWTH Aachen University, Faculty of Medicine, Joint Research Centre for Computational Biomedicine, Aachen 52057, Germany 3 ​ Molecular Tumor Biology, Department of General, Visceral and Transplantation Surgery, RWTH University Hospital, Pauwelsstraße 30, 52074 Aachen, Germany 4 ​ NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands 5 ​ ESCAM – European Surgery Center Aachen Maastricht, Germany and The Netherlands # ​ co-last authors: [email protected]; [email protected] ​ ​ ​ Running title: Chromosomal rearrangement attenuation in cancer Keywords: Cancer; Gene dosage; Proteomics; Copy-number variation; Protein complexes 1 bioRxiv preprint doi: https://doi.org/10.1101/093369; this version posted February 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Chromosomal rearrangements, despite being detrimental, are ubiquitous in cancer and often act as driver events.
    [Show full text]
  • LEUKOCYTE SURFACE ORIGIN of HUMAN At-ACID GLYCOPROTEIN (OROSOMUCOID)*
    LEUKOCYTE SURFACE ORIGIN OF HUMAN at-ACID GLYCOPROTEIN (OROSOMUCOID)* BY CARL G. GAHMBERG AND LEIF C. ANDERSSON (From the Department of Bacteriology and Immunology, and the Transplantation Laboratory, Department of Surgery IV, University of Helsinki, Helsinki 29, Finland) Human al-acid glycoprotein (orosomucoid) (o~I-AG)1 constitutes the main component of the seromucoid fraction of human plasma. It belongs to the acute phase proteins, which increase under conditions such as inflammation, pregnancy, and cancer (1, 2). al-AG has previously been found to be synthesized in liver (3), and after removal of terminal sialic acids, it is cleared from the circulation by binding to a receptor protein on liver cell plasma membranes (4). The structure of al-AG is well known. It is composed of a single polypeptide chain and contains 245% carbohydrate including a large amount of sialic acid. The carbohydrate is located in the first half of the peptide chain linked to asparagine residues (5, 6). The function of al-AG is unclear. However, Schmid et al. (5) and Ikenaka et al. (7) and reported that the amino acid sequence of the protein shows a significant homology with human IgG. This finding and the striking increase in inflammatory and lymphopro- liferative disorders made us consider the possibility that leukocytes could be directly involved in the synthesis and release of a~-AG. We report here the presence of a membrane form of al-AG, with an apparent tool wt of 52,000, on normal human lymphocytes, granulocytes, and monocytes. By the use of internal labeling with [3H]leucine in vitro, we demonstrate that the membrane protein is synthesized by lymphocytes.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/25/2021 07:25:24AM Via Free Access 812 M Andreassen and Others EUROPEAN JOURNAL of ENDOCRINOLOGY (2012) 166
    European Journal of Endocrinology (2012) 166 811–819 ISSN 0804-4643 CLINICAL STUDY GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist Mikkel Andreassen1, Jan Frystyk2,3, Jens Faber1,4 and Lars Østergaard Kristensen1 1Endocrine Unit, Laboratory of Endocrinology 54o4, Department of Internal Medicine O, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark, 2Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark and 3Medical Research Laboratories, Faculty of Health Sciences, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark and 4Faculty of Health Science, Copenhagen University, Copenhagen, Denmark (Correspondence should be addressed to M Andreassen; Email: [email protected]) Abstract Introduction: The GH/IGF1 axis may modulate inflammatory processes. However, the relationship seems complicated as both pro- and anti-inflammatory effects have been demonstrated. Methods/design: Twelve healthy volunteers (mean age 36, range 27–49 years) were treated in random order with increasing doses of GH for 3 weeks (first week 0.01 mg/kg per day, second week 0.02 mg/kg per day, and third week 0.03 mg/kg per day) or a GH receptor antagonist (pegvisomant; first week 10 mg/day and last two weeks 15 mg/day), separated by 8 weeks of washout. Circulating levels of the pro-inflammatory cytokines tumor necrosis factor a (TNFa (TNFA)), interleukin 6 (IL6), and IL1b (IL1B) and the acute phase proteins (APPs) C-reactive protein (CRP), haptoglobin, orosomucoid, YKL40 (CHI3L1), and fibrinogen were measured. Results: During GH treatment, IGF1 (median 131 (Inter-quartile range (IQR) 112–166) vs 390 (322– 524) mg/l, PZ0.002) increased together with TNFa (0.87 (0.74–1.48) vs 1.27 (0.80–1.69) ng/l, PZ0.003), IL6 (1.00 (0.83–1.55) vs 1.35 (0.80–4.28) ng/l, PZ0.045), and fibrinogen (9.2 (8.8–9.6) vs 11.1 (9.4–12.4) mM, PZ0.002).
    [Show full text]